Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

WuXi PharmaTech Reports Excellent Q2; Raises 2013 Guidance

publication date: Aug 13, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WuXi PharmaTech’s Q2 results showed the company is continuing its long-standing pattern of steady growth. Revenues were up 9.2% to $142 million and net income climbed 44% to $29.6 million. The company’s non-GAAP earnings were $.46 per share, which was seven cents ahead of consensus estimates. With half of 2013 now known, WuXi raised guidance for full-year 2013. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...